vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and JOINT Corp (JYNT). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $15.2M, roughly 1.4× JOINT Corp). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs 6.5%, a 0.7% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 3.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -28.6%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
CUE vs JYNT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $15.2M |
| Net Profit | $1.6M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | 9.0% | 4.9% |
| Net Margin | 7.2% | 6.5% |
| Revenue YoY | 1292.3% | 3.1% |
| Net Profit YoY | 116.7% | 5510.5% |
| EPS (diluted) | $0.05 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $15.2M | ||
| Q3 25 | $2.1M | $13.4M | ||
| Q2 25 | $3.0M | $13.3M | ||
| Q1 25 | $421.0K | $13.1M | ||
| Q4 24 | $1.6M | $14.7M | ||
| Q3 24 | $3.3M | $30.2M | ||
| Q2 24 | $2.7M | $30.3M | ||
| Q1 24 | $1.7M | $29.7M |
| Q4 25 | $1.6M | $991.1K | ||
| Q3 25 | $-7.4M | $855.0K | ||
| Q2 25 | $-8.5M | $93.4K | ||
| Q1 25 | $-12.3M | $967.8K | ||
| Q4 24 | — | $17.7K | ||
| Q3 24 | $-8.7M | $-3.2M | ||
| Q2 24 | $-10.2M | $-3.6M | ||
| Q1 24 | $-12.3M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | 9.0% | 4.9% | ||
| Q3 25 | -353.4% | 1.2% | ||
| Q2 25 | -292.3% | -8.6% | ||
| Q1 25 | -2921.4% | -5.2% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | -264.2% | -1.6% | ||
| Q2 24 | -390.6% | -5.9% | ||
| Q1 24 | -737.8% | -1.4% |
| Q4 25 | 7.2% | 6.5% | ||
| Q3 25 | -346.6% | 6.4% | ||
| Q2 25 | -287.1% | 0.7% | ||
| Q1 25 | -2911.4% | 7.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | -259.6% | -10.5% | ||
| Q2 24 | -382.7% | -11.9% | ||
| Q1 24 | -719.1% | 3.2% |
| Q4 25 | $0.05 | $0.06 | ||
| Q3 25 | $-0.07 | $0.06 | ||
| Q2 25 | $-0.09 | $0.01 | ||
| Q1 25 | $-0.17 | $0.06 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-0.17 | $-0.21 | ||
| Q2 24 | $-0.20 | $-0.24 | ||
| Q1 24 | $-0.25 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $15.1M |
| Total Assets | $42.2M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $23.6M | ||
| Q3 25 | $11.7M | $29.7M | ||
| Q2 25 | $27.5M | $29.8M | ||
| Q1 25 | $13.1M | $21.9M | ||
| Q4 24 | $22.5M | $25.1M | ||
| Q3 24 | $32.4M | $20.7M | ||
| Q2 24 | $30.0M | $17.5M | ||
| Q1 24 | $41.0M | $18.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $15.1M | ||
| Q3 25 | $13.2M | $22.7M | ||
| Q2 25 | $18.2M | $23.2M | ||
| Q1 25 | $6.6M | $22.8M | ||
| Q4 24 | $17.5M | $20.7M | ||
| Q3 24 | $25.4M | $20.5M | ||
| Q2 24 | $21.6M | $23.2M | ||
| Q1 24 | $30.0M | $26.2M |
| Q4 25 | $42.2M | $61.0M | ||
| Q3 25 | $31.6M | $69.4M | ||
| Q2 25 | $40.7M | $73.2M | ||
| Q1 25 | $22.3M | $80.1M | ||
| Q4 24 | $32.2M | $83.2M | ||
| Q3 24 | $44.8M | $79.6M | ||
| Q2 24 | $42.3M | $82.4M | ||
| Q1 24 | $54.0M | $85.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $1.8M |
| Free Cash FlowOCF − Capex | — | $334.7K |
| FCF MarginFCF / Revenue | — | 2.2% |
| Capex IntensityCapex / Revenue | 0.0% | 9.9% |
| Cash ConversionOCF / Net Profit | -0.68× | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $1.8M | ||
| Q3 25 | $-9.0M | $1.8M | ||
| Q2 25 | $-3.4M | $868.6K | ||
| Q1 25 | $-8.2M | $-3.7M | ||
| Q4 24 | $-36.3M | $9.4M | ||
| Q3 24 | $-7.5M | $3.4M | ||
| Q2 24 | $-10.0M | $-973.5K | ||
| Q1 24 | $-9.8M | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | $-3.4M | $363.6K | ||
| Q1 25 | $-8.3M | $-4.0M | ||
| Q4 24 | $-36.4M | $8.2M | ||
| Q3 24 | $-7.5M | $3.2M | ||
| Q2 24 | $-10.0M | $-1.2M | ||
| Q1 24 | $-9.8M | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 10.9% | ||
| Q2 25 | -116.5% | 2.7% | ||
| Q1 25 | -1976.7% | -30.8% | ||
| Q4 24 | -2309.3% | 55.9% | ||
| Q3 24 | -225.7% | 10.6% | ||
| Q2 24 | -376.2% | -4.1% | ||
| Q1 24 | -573.0% | 8.1% |
| Q4 25 | 0.0% | 9.9% | ||
| Q3 25 | 0.0% | 2.4% | ||
| Q2 25 | 0.9% | 3.8% | ||
| Q1 25 | 35.6% | 2.5% | ||
| Q4 24 | 4.2% | 8.1% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 3.2% | 1.3% |
| Q4 25 | -0.68× | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
